Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (SBIR [R43/44])
| Jurisdiction: |
Federal
|
| Incentive Type: | Grant Program |
| Industries: |
Medical, Education, Health And Safety
|
| Eligible Sector: |
Business
|
| Category: |
Financial Incentive
|
| Time Period: |
FY 2015
|
| Governing Body: | National Institutes of Health |
| What’s it worth?: | Not mentioned |
The Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care program encourages research for commercial development of new cancer-relevant technologies. These research projects are expected to further develop highly-innovative technologies used to overcome challenges of cancer research or clinical care. Technological areas of interest include but are not excluded to:
- Technology capable of converting basic mechanisms underlying cancer initiation and progression.
- Technology to improve early cancer detection and/or cancer risk assessment
- Technology to distinguish, assess, and/or monitor cancer progression
- Technology to assist in the drug discovery or development
- Technology to enhance molecular analyses in cancer epidemiology
- Technology for sample preparation and processing
- Technology that provides a new means for general analyte quality assessment
- Technology or tools that help penetrate research barriers on the incidence, prevalence, mortality, and burden of cancer among members of undeserved populations
Typical award amounts of not more than $225,000 for Phase I projects and up to $1,500,000 for Phase II projects with project duration of up to two years. All applicants must meet the following criteria.
